Highlights Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 13/03/2026 pm IST			5-day change	1st Jan Change
110.20 ^HKD	-0.81%		+2.70%	-2.48%

05/03	Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral	MT
05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer	CI

Highlights

05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer	CI
04/03	INOVIO and Akeso Enter Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma	CI
11/02	Akeso, Inc.'s IL-4Ra/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	CI
06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE
03/02	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
19/01	Akeso, Inc. Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis	CI
14/01	Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	CI
13/01	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
07/01	Akeso, Inc. Announces the National Medical Products Administration Approves Significant Label Update in China for its Internally Develop, PD-1/VEGF Bispecific Antibody, ivonescimab	CI
12/12	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab	CI
11/12	Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025	CI
09/12	Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress	CI
09/12	Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	CI
17/11	Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China	CI
10/11	Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer	CI
07/11	Akeso, Inc. Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody At SITC 2025	CI
07/11	Akeso Announces Final OS Analysis Results Of Ivonescimab HARMONi-A Study At SITC 2025	CI
03/11	Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer	CI
31/25/31	Summit Therapeutics Inc. Announces Results from the Phase III Harmoni-A Trial, Conducted in China and Sponsored by Akeso, Inc	CI
19/25/19	Akeso Announces Results of the Registrational Phase III Clinical Study Evaluating Ivonescimab (PD-1/VEGF Bispecific Antibody)	CI
19/25/19	Summit Intends to Open Clinical Trial Sites in the United States for the Phase Iii Harmoni-Gi3 Study in Colorectal Cancer by the End of 2025	CI
16/25/16	HARMONi-6 Phase III Study of Ivonescimab Accepted by the Lancet and Selected for ESM0 2025 LBA Presentation	CI
23/25/23	Akeso Inc. Announces Late-Breaking abstract from the Registrational Phase III Clinical Study (AK-306/HARMONi-6 Study) of Ivonescimab	CI